Palliative hypnosis approaches in the symptomatic treatment of amyotrophic lateral sclerosis (ALS)

被引:2
作者
Franklin, John E. [1 ,2 ]
机构
[1] Med Univ South Carolina, Charleston, SC USA
[2] Med Univ South Carolina, Dept Vet Affairs, Med Ctr, POB 12728, Charleston, SC 29422 USA
关键词
ALS; amyotrophic lateral sclerosis; hypnosis; palliative; SEVERE CHRONIC DISEASES; OF-LIFE; CLINICAL HYPNOSIS; DIGNITY THERAPY; ANXIETY; CARE; END; DEPRESSION; EXPERIENCE;
D O I
10.1080/00029157.2023.2252875
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Amyotrophic lateral sclerosis (ALS) is a rare, incurable, and ultimately fatal, devastating, progressive degenerative neurologic disease. It causes upheaval in the lives of patients and family caregivers alike. Palliative care can play an important supportive role in the care of patients and families dealing with the devastation of this illness. Clinical hypnosis has demonstrated benefits in treating the symptoms associated with severe chronic illness. There are, however, few studies looking at the benefits of clinical hypnosis in treating the symptom burden of ALS. This article describes palliative care and how it can provide an additional layer of support to seriously ill patients. A brief review of previous studies of hypnosis in the supportive, symptomatic treatment of ALS is provided, followed by a description of a case series of 30 Veterans who received clinical hypnosis and self-hypnosis training as a complementary treatment for the symptoms of ALS. Details of three case histories are included to highlight and discuss specific strategies and emblematic clinical responses. There is evidence that clinical hypnosis can benefit ALS patients and family caregivers struggling with this devastating illness.
引用
收藏
页码:54 / 68
页数:15
相关论文
共 50 条
  • [31] The evidence for symptomatic treatments in amyotrophic lateral sclerosis
    Jenkins, Thomas M.
    Hollinger, Hannah
    McDermott, Christopher J.
    [J]. CURRENT OPINION IN NEUROLOGY, 2014, 27 (05) : 524 - 531
  • [32] Palliative care at any stage of amyotrophic lateral sclerosis: a prospective feasibility study
    Zwicker, Jocelyn
    Smith, Ian C.
    Rice, Jill
    Murphy, Rebekah
    Breiner, Ari
    McNeely, Susan
    Duff, Maria
    Buenger, Usha
    Zehrt, Belinda
    Nogo, Danica
    Watt, Christine L.
    [J]. FRONTIERS IN MEDICINE, 2023, 10
  • [33] Life Patterns of Family Caregivers of Patients With Amyotrophic Lateral Sclerosis
    Shipley, Peggy Z.
    Falkenstern, Sharon K.
    [J]. NURSING SCIENCE QUARTERLY, 2023, 36 (04) : 356 - 368
  • [34] Treatment of Amyotrophic Lateral Sclerosis
    Andrew Eisen
    Markus Weber
    [J]. Drugs & Aging, 1999, 14 : 173 - 196
  • [35] Overview of Lipid Biomarkers in Amyotrophic Lateral Sclerosis (ALS)
    Trostchansky, Andres
    [J]. ROLE OF BIOACTIVE LIPIDS IN CANCER, INFLAMMATION AND RELATED DISEASES, 2019, 1161 : 233 - 241
  • [36] A specific phobia of amyotrophic lateral sclerosis (ALS phobia)
    Levitsky, G. N.
    Gilod, V. M.
    Levin, O. S.
    [J]. ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2012, 112 (08) : 4 - 6
  • [37] The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS)
    Boddy, Sarah L.
    Giovannelli, Ilaria
    Sassani, Matilde
    Cooper-Knock, Johnathan
    Snyder, Michael P.
    Segal, Eran
    Elinav, Eran
    Barker, Lynne A.
    Shaw, Pamela J.
    McDermott, Christopher J.
    [J]. BMC MEDICINE, 2021, 19 (01)
  • [38] Speech intelligibility in people with Amyotrophic Lateral Sclerosis (ALS)
    Leite Neto, Lavoisier
    Franca Junior, Marcondes Cavalcante
    Chun, Regina Yu Shon
    [J]. CODAS, 2021, 33 (01):
  • [39] VEGF promoter haplotype and amyotrophic lateral sclerosis (ALS)
    Terry, PD
    Kamel, F
    Umbach, DM
    Lehman, TA
    Hu, H
    Sandler, DP
    Taylor, JA
    [J]. JOURNAL OF NEUROGENETICS, 2004, 18 (02) : 429 - 434
  • [40] Personalized Precision Immunotherapy for Amyotrophic Lateral Sclerosis (ALS)
    Maharaj, Dipnarine
    Kaur, Kawaljit
    Saltese, Adrian
    Gouvea, Jacqueline
    [J]. CRITICAL REVIEWS IN IMMUNOLOGY, 2023, 43 (02) : 1 - 11